Résumé
Abstract only
- Titre
- Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study
- Créateurs - sans rôle
- Suzette Delaloge - Institut Gustave RoussyDavid Pérol - Centre Léon BérardEtienne Brain - Centre Rene Huguenin, St Cloud, FranceBernard Asselain - Institut Curie, Paris, FranceThomas Denis Bachelot - Centre Léon BérardMarc Debled - Institut BergoniéVeronique Dieras - Institut CurieMario Campone - Cancer Institute of the West (ICO), Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, FranceChristelle Levy - Centre François Baclesse, Caen, FranceWilliam Jacot - Institut du Cancer de Montpellier, Montpellier, FranceVeronique Lorgis - Centre Georges François LeclercCorinne Veyret - Department of Medical Oncology, Henri Becquerel Center, Rouen, FranceFlorence Dalenc - Institut Claudius RegaudJean-Marc Ferrero - Department d'Oncologie Medicale, Centre Antoine Lacassagne, Nice, FranceLionel Uwer - Centre Alexis Vautrin, Nancy, FranceAnthony Goncalves - Institut Paoli-CalmettesIrwin Piot - UNICANCER, Paris, FranceGaetane Simon - UNICANCER, Paris, FranceMathieu Robain - UNICANCER, Paris, FranceChristian Cailliot - UNICANCER, Paris, France
- Détails de publication
- Journal of clinical oncology, Vol.34(15_suppl), pp.1013-1013
- Identifiants
- 99140047409311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article